Endocrinology Medical News about Exenatide Sitagliptin

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
CMS Revises Consignment Closet Provisions

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

FDA Approves Revisions to Prescribing Information for Diabetes Medications
American Family Physician, 11/06/09

The FDA is revising the prescribing information for the injectable diabetes medication exenatide and the oral diabetes drug sitagliptin phosphate following reports of renal problems associated with exenatide use, as well as reports linking sitagliptin use with pancreatitis.

<< Previous
Higher Serum Testosterone Concentration in Older Women is...

Next >>
From somatostatin to octreotide LAR: evolution of a somatostatin...